Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 2,347 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Intravenous Clear all
Terminated Phase 1 Interventional

Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer

NCT00529113
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreatic Cancer
Interventions
Bardoxolone methyl, Gemcitabine, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
Denver, Colorado • Ocoee, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 14, 2026, 1:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

NCT01610388
View directory record Official record
Conditions
Infections, Bacterial
Interventions
500mg IV GSK1322322/placebo, 1000mg oral GSK1322322/placebo, 1000mg IV GSK1322322/placebo, 1500mg oral GSK1322322/placebo dose, 1500mg IV GSK1322322/placebo, 2000mg IV GSK1322322J/placebo, 3000mg IV GSK1322322J/placebo, 1000mg IV GSK1322322J/placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 14, 2026, 1:17 AM EDT
Terminated Phase 4 Interventional Results available

Steroid Administration for Articular Fractures of the Elbow (SAFE Trial)

NCT04738318
View directory record Official record
Conditions
Elbow Fracture
Interventions
Glucocorticoids, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 14, 2026, 1:17 AM EDT
Completed Phase 2 Interventional

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

NCT01466374
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, BMS-936557 (Anti-IP-10 Antibody)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
10
States / cities
Santa Monica, California • Winter Park, Florida • Hammond, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 14, 2026, 1:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants

NCT06774313
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-142, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 14, 2026, 1:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

NCT02439359
View directory record Official record
Conditions
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Interventions
CF-301, Placebo
Drug
Lead sponsor
ContraFect
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Lenexa, Kansas • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 14, 2026, 1:17 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Vitamin B12 in Septic Shock

NCT03783091
View directory record Official record
Conditions
Septic Shock
Interventions
Hydroxocobalamin, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 14, 2026, 1:17 AM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

NCT03318523
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Placebo, BIIB054
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 80 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 14, 2026, 1:17 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI

NCT00546260
View directory record Official record
Conditions
Myocardial Infarction
Interventions
placebo, PRT060128 Potassium
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Tallahassee, Florida • Des Moines, Iowa • Lexington, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 14, 2026, 1:17 AM EDT
Completed Phase 2 Interventional

Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants

NCT00349726
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions
Inositol lower volume, Inositol higher volume, Placebo lower volume, Placebo higher volume
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
3 Days to 6 Days
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
11
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 14, 2026, 1:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers

NCT02341508
View directory record Official record
Conditions
Healthy Subjects
Interventions
0.5 mg/kg Lpathomab, 1.0 mg/kg Lpathomab, 3.0 mg/kg Lpathomab, 10 mg/kg Lpathomab, 20 mg/kg Lpathomab, Saline solution for intravenous infusion
Biological · Other
Lead sponsor
Lpath, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 14, 2026, 1:17 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

NCT01405508
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 14, 2026, 1:17 AM EDT
Completed Phase 1 Interventional Results available

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

NCT01673178
View directory record Official record
Conditions
Diabetes Melliuts, Type 2
Interventions
Placebo, 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023, 150 mg PF-05231023
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
17
States / cities
Anaheim, California • Chula Vista, California • Walnut Creek, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 14, 2026, 1:17 AM EDT
Completed Phase 3 Interventional Results available

Methotrexate-Inadequate Response Study

NCT00559585
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Subcutaneous (SC) Abatacept, Intravenous (IV) Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
2,492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
70
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Oct 14, 2026, 1:17 AM EDT
Suspended Phase 3 Interventional

Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy

NCT05324358
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Ketorolac Tromethamine, Morphine Sulfate, Intravenous Placebo for NTM-001, IV Placebo for Morphine
Drug · Other
Lead sponsor
Neumentum, Inc.
Other
Eligibility
18 Years to 64 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Sun City, Arizona • Bakersfield, California • Canoga Park, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 14, 2026, 1:17 AM EDT
Completed Phase 2 Interventional Results available

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

NCT01747551
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Oxaliplatin, Leucovorin, Fluorouracil, Ziv-aflibercept
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 14, 2026, 1:17 AM EDT
Completed Phase 1 Interventional

Intravenous Zotatifin in Adults With Mild or Moderate COVID-19

NCT04632381
View directory record Official record
Conditions
Corona Virus Infection
Interventions
Zotatifin, Placebo
Drug
Lead sponsor
Effector Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Anniston, Alabama • Cullman, Alabama • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 14, 2026, 1:17 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

NCT00130728
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
bevacizumab, erlotinib HCl, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
4
States / cities
Vallejo, California • Athens, Georgia • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 14, 2026, 1:17 AM EDT
Completed Not applicable Interventional

A Study of Isoprinosine in Patients With Severe AIDS

NCT00002295
View directory record Official record
Conditions
HIV Infections
Interventions
Inosine pranobex
Drug
Lead sponsor
Newport Pharmaceuticals International
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 1:17 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Vapocoolant Spray to Reduce Pain With Nexplanon Insertion

NCT06933381
View directory record Official record
Conditions
Reducing Pain With Nexplanon Implant Insertion
Interventions
Vapocoolant spray, Placebo
Device · Other
Lead sponsor
Queen's Medical Center
Other
Eligibility
14 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Honolulu, Hawaii • Waimea, Hawaii
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 1:17 AM EDT
Recruiting Phase 1Phase 2 Interventional

Ocrelizumab for Psychosis by Autoimmunity

NCT03971487
View directory record Official record
Conditions
Schizo-Affective Type of Psychosis, Schizophrenia
Interventions
Psychosis and cognitive assessments, Physical and neuro-cognitive evaluations, Safety labs and electrocardiogram, Ocrelizumab infusion
Behavioral · Diagnostic Test · Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 14, 2026, 1:17 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

NCT03059355
View directory record Official record
Conditions
Endothelial Dysfunction, Metabolic Syndrome, Chronic Inflammation
Interventions
UCMSCs, BMMSCs, Placebo
Biological · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 95 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 14, 2026, 1:17 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients

NCT06409819
View directory record Official record
Conditions
Urinary Tract Infection, Recurrent
Interventions
phage therapy, control
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 14, 2026, 1:17 AM EDT
Terminated Phase 1 Interventional

Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)

NCT03116971
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
M3814, Cisplatin, Etoposide
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
16
States / cities
Mesa, Arizona • Santa Rosa, California • Whittier, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 14, 2026, 1:17 AM EDT